Nephrology Times

02/17/2025

Previous studies suggest a link between CKD and sleep disorders, but the nature of the association is not clearly defined.

Previous studies suggest a link between chronic kidney disease (CKD) and sleep disorders, but the nature of the association is unclear.

02/16/2025

DON'T MISS OUT on the latest neph news, delivered right to your inbox. Sign up now for our e-newsletters ➡️ https://buff.ly/4c58U8y

02/15/2025

DID YOU KNOW you can catch up with research highlights from major conferences, including WCN25, on our website?

View updates and commentary from major conferences for nephrologists, reported by Nephrology Times editors.

02/14/2025

In his latest column, Ajay Singh pays tribute to the late nephrologist Dr. Barry Brenner.

Dr. Ajay Singh and others pay tribute to Dr. Barry Brenner, a leading nephrologist who passed away in August 2024.

02/13/2025

Researchers used NHANES data to investigate a potential association between gout and kidney stones.

A study examined the relationship between gout and kidney stones using NHANES data.

02/13/2025

KidneyVault transported four donor kidneys to four separate medical institutions across the US in a 24-hour period in December.

The KidneyVault Portable Renal Perfusion System by Paragonix Technologies has been used in human kidney transplants for the first time.

02/12/2025

How safe is kidney transplantation from donors with HIV to recipients with HIV?

A study examined the safety and noninferiority of kidney transplantation from donors with human immunodeficiency virus (HIV) to recipients with HIV.

02/12/2025

A phase II trial of was terminated "due to a lack of foreseeable clinical benefit" in .

Eli Lilly ended a phase II trial of volenrelaxin, an investigational synthetic analog relaxin, in chronic kidney disease (CKD) "due to a lack of foreseeable clinical benefit."

02/11/2025

Travere will submit an sNDA requesting traditional approval of sparsentan (Filspari) for FSGS by the end of Q1 2025.

Travere Therapeutics will submit a supplemental New Drug Application to the FDA requesting approval of sparsentan (Filspari) to treat focal segmental glomerulosclerosis (FSGS).

02/11/2025

Research examined the efficacy and safety of the use of statins among kidney allograft recipients. https://buff.ly/4hHTxVE

02/10/2025

A study compared the renoprotective benefits of metabolic surgery to GLP-1RA in obesity and CKD.

A study assessed the kidney benefits of metabolic surgery compared to glucagon-like peptide-1 receptor agonist treatment in patients with obesity and chronic kidney disease (CKD).

02/09/2025

The World Congress of Nephrology wraps up today. Couldn't attend? Check out research highlights at nephtimes.com

02/08/2025

The latest episodes of the and podcasts are available on our website.

Nephrology Times is proud to feature Freely Filtered and Channel Your Enthusiasm, leading health care podcasts covering the latest research in the nephrology space.

02/07/2025

The NKF Innovation Fund will support development of the NoMo Kidney Pump, a next-generation preservation technology.

The National Kidney Foundation Innovation Fund will invest in Northernmost's NoMo Kidney Pump, a continuous perfusion system to modernize donor kidney preservation and storage.

02/07/2025

A study sought to shed light on whether GLP-1 receptor agonists reduce the risk of significant kidney outcomes and whether they have and benefits for patients without .

A study examined whether GLP-1 receptor agonists improved clinically important kidney outcomes and whether patients without diabetes could benefit from treatment with them.

02/07/2025

A study of DKD drug monlunabant failed to meet its primary endpoint, but not all the kidney disease news in Novo Nordisk's 2024 financial report was bleak.

Monlunabant failed in a study of its use in diabetic kidney disease (DKD), but Novo Nordisk had positive news about other kidney treatments in its 2024 financial report.

02/07/2025

Two FDA designations will help support the development and evaluation of Arbor's ABO-101 to treat primary hyperoxaluria type 1.

The FDA has granted orphan drug and rare pediatric disease designations to ABO-101 to treat primary hyperoxaluria type 1 (PH1).